Cover photo shows the MRX004 Soft Mist Inhaler, used in the development of advanced inhaled therapies. Courtesy of Merxin Ltd., No.1 Innovation Drive, King’s Lynn, Norfolk, PE30 5BY, United Kingdom, Tel.: +44 1553 403070, info@merxin.com, www.merxin.com.
V o l u m e 1 9 N u m b e r 1 F e b r u a r y 2 0 2 5
Inhalation
CLICK HERE
TO RENEW TODAY!
Analytical challenges
and regulatory
perspectives in
SMI development
An inhalable
nanoparticle-based
siRNA therapy for
betacoronavirus
infections
Cross-industry
organizations:
Inhalation's partners
Back pages: Asthma
extent and control
in children of
US and Africa
